Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Epcoritamab With Lenalidomide and Tafasitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL)

NCT07030699 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07030699
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07030699 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Epcoritamab With Lenalidomide and Tafasitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Withdrawn
Start date
August 13, 2025
Completion date
March 31, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma